+++
title = "Pfizer expects $54 billion in 2022 sales on Covid vaccine and treatment pill"
description = "Pfizer expects to sell $32 billion of its Covid-19 shots and $22 billion of its antiviral coronavirus treatment pill Paxlovid."
date = "2022-02-09 00:44:21"
slug = "62030e3e3d8878d511b366da"
image = "https://i.imgur.com/kC20tNS.jpg"
score = "1058"
categories = ['revenue', 'sales', 'vaccine']
+++

Pfizer expects to sell $32 billion of its Covid-19 shots and $22 billion of its antiviral coronavirus treatment pill Paxlovid.

## Highlights

- Pfizer's fourth-quarter revenue more than doubled overall to $23.84 billion year-over-year, driven by $12.5 billion in sales of its Covid vaccine.
- Pfizer CEO Albert Bourla said sales of Paxlovid could be higher than the company's guidance, but the expectations are based on deals signed or close to being signed.
- The company's share was down more than 5.7% in morning trading.
- On an unadjusted basis, Pfizer profit increased more than fourfold to $3.39 billion from $847 million during the same three months in 2020.
- Pfizer expects $98 billion to $102 billion in revenue for 2022.

---

{{< rawhtml >}}
  <p class="article-category">
    <a target="_blank" href="https://www.cnbc.com/2022/02/08/covid-pfizer-pfe-earnings-q4-2021.html">READ THE ORIGINAL ARTICLE</a>
  </p>
{{< /rawhtml >}}
